Maxcyte price to sales ratio MXCT

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 4.7×
5-year median: 9.5×
Against its 5-year history: 23rd; percentile: 0 is its lowest day, 100 its highest
5-year range: 2.2× to 21.3×
Peer median: 2.2×

Maxcyte's price to sales ratio is 4.7× as of Oct 23, 2026.

That is below its 5-year median of 9.5×, lower than on 77% of days in the last 5 years.

Over that time it ranged from 2.2× in Mar 2026 to 21.3× in Mar 2022.

The median for 10 healthcare stocks of a similar size is 2.2×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	4.7×	2.2×	4.8×
2025	5.0×	4.1×	11.4×
2024	9.6×	7.8×	14.6×
2023	12.8×	7.3×	14.0×
2022	13.3×	10.0×	21.3×

Against its peers

Companies in Healthcare nearest Maxcyte's size, closest first, today.

Company	Price to sales ratio
MXCTMaxcyte	4.7×
PDEXPro DEX	2.6×
PLXProtalix BioTherapeutics	2.5×
NATRNatures Sunshine Products	0.4×
KEQUKewaunee Scientific	0.3×
ELMDElectromed	3.0×
ICCCImmucell	3.0×
UTMDUtah Medical Products	6.5×
INFUInfuSystem	1.9×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
Peer median	2.2×

Where Maxcyte ranks

#33of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Maxcyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.